Damora Therapeutics, Inc.
DMRA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.3B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.30 Billion |
|---|---|
| Enterprise Value | $761.49 Million |
| Earnings per Share | $-152.99 |
| Beta | 1.44 |
| Outstanding Shares | 61,135,145 |
Return
| Return on Equity | -50.93% |
|---|---|
| Return on Assets | -48.35% |
| Return on Invested Capital | -18.67% |
Valuation & Multiples
| P/E Ratio | -0.17 |
|---|---|
| PEG | -0.02 |
| Price to Sales | - |
| Price to Book Ratio | 2.75 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.9 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.41
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.48
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 105.64%▼ 57.62% |
|---|---|
| Total Invested | $1.68B▲ 15.54% |
| Investors Holding | 103▲ 39.00% |
About Galecto Inc
28 employees
CEO: Jennifer A. Jarrett
Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leadi...